Altimmune, Inc. (NASDAQ:ALT) Receives Average Rating of “Buy” from Analysts

Posted by AM Reporter Staff on Aug 6th, 2022

Shares of Altimmune, Inc. (NASDAQ:ALT – Get Rating) have received an average recommendation of “Buy” from the six analysts that are covering the firm, MarketBeat reports. Four analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $25.00.

A number of analysts recently weighed in on the stock. JMP Securities reiterated a “buy” rating and set a $22.00 price target on shares of Altimmune in a research note on Wednesday, June 1st. Guggenheim reduced their target price on shares of Altimmune to $27.00 and set a “na” rating for the company in a research note on Monday, May 16th. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of Altimmune in a research note on Tuesday, July 5th. Finally, Piper Sandler reduced their target price on shares of Altimmune from $34.00 to $25.00 and set an “overweight” rating for the company in a research note on Tuesday, May 17th.

Altimmune Trading Up 6.0 %

Shares of NASDAQ:ALT opened at $12.40 on Friday. Altimmune has a 52 week low of $3.83 and a 52 week high of $17.26. The company’s 50 day moving average is $10.18 and its two-hundred day moving average is $7.59. The company has a market cap of $535.92 million, a PE ratio of -5.12 and a beta of 0.48.

Altimmune (NASDAQ:ALT – Get Rating) last posted its earnings results on Thursday, May 12th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.13. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $2.06 million. Altimmune had a negative net margin of 2,819.11% and a negative return on equity of 43.28%. During the same period last year, the firm posted ($0.38) EPS. As a group, equities research analysts expect that Altimmune will post -1.9 EPS for the current year.

Insider Buying and Selling at Altimmune

In other Altimmune news, insider M Scot Roberts sold 37,352 shares of Altimmune stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $12.00, for a total transaction of $448,224.00. Following the transaction, the insider now directly owns 17,700 shares of the company’s stock, valued at $212,400. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, insider M Scot Roberts sold 37,352 shares of Altimmune stock in a transaction on Monday, June 27th. The shares were sold at an average price of $12.00, for a total value of $448,224.00. Following the completion of the sale, the insider now owns 17,700 shares in the company, valued at $212,400. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Diane Jorkasky sold 17,610 shares of Altimmune stock in a transaction on Monday, June 27th. The stock was sold at an average price of $11.75, for a total transaction of $206,917.50. The disclosure for this sale can be found here. Insiders have sold a total of 97,588 shares of company stock valued at $1,166,654 over the last ninety days. Corporate insiders own 3.14% of the company’s stock.

Institutional Trading of Altimmune

Several institutional investors have recently added to or reduced their stakes in ALT. Amalgamated Bank bought a new position in shares of Altimmune during the first quarter worth about $29,000. FNY Investment Advisers LLC bought a new position in shares of Altimmune during the second quarter worth about $31,000. Emfo LLC bought a new position in shares of Altimmune during the second quarter worth about $44,000. Point72 Hong Kong Ltd bought a new position in shares of Altimmune during the fourth quarter worth about $49,000. Finally, Graham Capital Management L.P. bought a new position in shares of Altimmune during the first quarter worth about $63,000. Institutional investors own 88.00% of the company’s stock.

About Altimmune

(Get Rating)

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis.